A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...

In the BOHEMIA study, once-monthly ivermectin over 3 months significantly reduced malaria incidence versus albendazole in children aged 5 to 15 years, supporting its role as a novel vector-control ...

Pasithea completes enrollment and initial dosing of first Cohort from its phase 1/1b trial of PAS-004 in adult NF1 patients: Miami Saturday, August 2, 2025, 18:00 Hrs [IST] Pasith ...

ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms - ...

Alterity Therapeutics has reported positive topline results from its open-label phase II clinical trial of lead drug ATH434, ...

Healthcare shared topline results from its RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate for ...

Namodenoson is a highly selective A3 adenosine receptor (A3AR) agonist, which has shown a compelling safety profile and ...

AbbVie (NYSE: ABBV) today announced positive topline results from the first of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ®; 15 ...

Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic ...

On this week's Health Matters, WVUA 23 Anchor Carlie Horn sat down with University of Alabama College of Community Health ...